This bill, titled the "End Tuberculosis Now Act of 2026," amends Section 104B of the Foreign Assistance Act of 1961 to significantly bolster United States foreign assistance programs aimed at combating tuberculosis (TB) globally. It declares that ending the TB public health emergency is a major objective of U.S. foreign assistance, focusing on supporting the diagnosis, treatment, and prevention of all forms of TB. The legislation outlines a comprehensive policy for U.S. engagement, particularly in countries with high rates of TB. Key strategies include developing and utilizing innovative technologies like molecular diagnostics, expanding treatment for all forms of TB (including latent TB and for children and individuals with HIV), and ensuring high-quality care through continuous improvement and sustainable procurement of commodities. It also emphasizes implementing robust infection control, deploying diagnostic capacity to high-burden areas, and training healthcare workers. The bill authorizes the President to furnish assistance, prioritizing the strengthening of TB programs, direct high-quality care, and research and development for new diagnostics, drugs, and vaccines. It also seeks to reduce barriers to treatment costs and integrate TB activities into primary healthcare systems. Furthermore, the legislation encourages coordination with the private sector for research and development, as well as improving existing tools. Specific goals are established for the period between 2027 and 2030, aiming to reduce TB incidence by 80 percent and mortality by 90 percent from 2015 levels. Other targets include achieving 90 percent diagnosis and treatment initiation for all TB cases, including drug-resistant forms, and providing preventive treatment to 30 million individuals. The bill also requires an update to the National Action Plan for Combating Multidrug-Resistant Tuberculosis. To ensure effective implementation, the bill mandates coordination with partner nations, international organizations, non-governmental organizations, and the private sector, as well as among relevant U.S. federal departments and agencies. It requires annual reports to Congress on the activities, impact, and research and development progress of U.S. global TB efforts until December 31, 2032. Additionally, the Comptroller General is tasked with submitting an evaluation report on program performance and impact by 2030. The amendments made by this bill are set to cease effect on January 1, 2033.